GlassScriptPhysician profile
Michael L Kane
NPI 1942276654
$3,420.62
in general payments reported to CMS, 2019-2025
14 companies · $260 in 2025
The $260 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $454 · 2020: $70.56 · 2022: $197 · 2023: $245 · 2024: $2,195 · 2025: $260.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Debt Forgiveness: $2,170 · Food and Beverage: $530.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Debt Forgiveness | $2,169.50 |
| Food and Beverage | $530.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $2,198.09 | 2019-2024 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $156.77 | 2019-2020 | |
| Lkc Technologies, INC. | $139.51 | 2023 | |
| Aerie Pharmaceuticals, INC. | $127.47 | 2019 | |
| Genzyme Corporation | $121.95 | 2019 | |
| Sun Pharmaceutical Industries INC. | $121.82 | 2025 | |
| Dompe US, INC. | $121.77 | 2025 | Oxervate |
| Johnson & Johnson Vision Care, INC. | $120.25 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $105.23 | 2023 | Infuse |
| Carl Zeiss Meditec USA, INC. | $88.04 | 2022 | |
| Optos, INC. | $58.64 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $25.53 | 2024 | Xdemvy |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Alcon Vision LLC | $16.15 | 2025 | Precision 1 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Kane listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.